Colton Groome Financial Advisors LLC Grows Stock Position in AbbVie Inc. $ABBV

Colton Groome Financial Advisors LLC grew its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 50.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,274 shares of the company’s stock after acquiring an additional 2,767 shares during the quarter. Colton Groome Financial Advisors LLC’s holdings in AbbVie were worth $2,165,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. State Street Corp lifted its stake in AbbVie by 1.7% in the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after purchasing an additional 1,379,232 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of AbbVie by 0.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock valued at $3,590,323,000 after acquiring an additional 106,091 shares during the last quarter. Franklin Resources Inc. boosted its holdings in shares of AbbVie by 2.3% during the 4th quarter. Franklin Resources Inc. now owns 14,881,504 shares of the company’s stock valued at $3,400,274,000 after acquiring an additional 330,104 shares in the last quarter. Legal & General Group Plc bought a new stake in AbbVie during the 2nd quarter worth $2,905,952,000. Finally, Deutsche Bank AG grew its position in AbbVie by 13.0% during the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock worth $2,710,905,000 after acquiring an additional 1,241,587 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive lymphoma trial results: AbbVie and Genmab reported that the Phase 3 EPCORE DLBCL-2 trial met its primary endpoint. Adding epcoritamab to R-CHOP produced a statistically significant and clinically meaningful improvement in progression-free survival for newly diagnosed diffuse large B-cell lymphoma patients. The companies plan to discuss the data with global regulators, strengthening AbbVie’s longer-term oncology growth prospects. AbbVie and Genmab EPCORE DLBCL-2 results
• Positive Sentiment: Higher analyst price target: Scotiabank raised its AbbVie target from $280 to $320 and reiterated a “sector outperform” rating, signaling confidence in the company’s earnings outlook and drug pipeline. Wall Street’s broader analyst view also remains favorable. Scotiabank raises AbbVie price target
• Neutral Sentiment: Upcoming third-quarter results: AbbVie is scheduled to report its third-quarter results later this month, with investors likely focused on Humira-related trends, newer immunology products, and whether the company can support its full-year outlook. Should You Buy AbbVie Stock Before Oct. 30?
• Neutral Sentiment: Additional pipeline and pricing developments: AbbVie’s FDA-approved Parkinson’s treatment and participation in a federal 340B rebate pilot could expand its commercial reach, although the longer-term financial impact remains uncertain.
• Negative Sentiment: Reduced third-quarter guidance: AbbVie now expects adjusted Q3 EPS of $3.73–$3.77, below the $3.85 consensus estimate. The company cited $216 million in acquired research, development, and milestone expenses; full-year adjusted EPS guidance was lowered by $0.11 to $13.76–$13.96. AbbVie updates 2026 EPS guidance

Analyst Upgrades and Downgrades

ABBV has been the subject of several research reports. Citigroup increased their target price on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Royal Bank Of Canada upped their price target on shares of AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research report on Friday, July 10th. JPMorgan Chase & Co. raised their price target on shares of AbbVie from $280.00 to $285.00 and gave the company an “overweight” rating in a research note on Thursday, July 30th. Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and boosted their price objective for the stock from $235.00 to $300.00 in a research note on Thursday, August 13th. Finally, Leerink Partners increased their price objective on AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $273.82.

AbbVie Stock Performance

Shares of NYSE:ABBV traded up $1.53 during trading on Tuesday, reaching $267.29. The stock had a trading volume of 1,479,835 shares, compared to its average volume of 6,420,333. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $269.39. The firm’s fifty day moving average is $258.05 and its 200 day moving average is $235.01. The stock has a market cap of $472.25 billion, a price-to-earnings ratio of 75.47, a P/E/G ratio of 1.19 and a beta of 0.24.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the previous year, the business earned $2.97 earnings per share. AbbVie’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts forecast that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.6%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.